|Day's Range||885.00 - 940.00|
|52 Week Range||686.15 - 1,188.00|
|PE Ratio (TTM)||20.99|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.
Categories: Asia Pacific Value Yahoo FinanceClick here to see latest analysis Capitalcube gives Biocon Ltd. a score of 66. Our analysis is based on comparing Biocon Ltd. with the following peers – Jubilant Life Sciences Limited, Pfizer India Ltd., Piramal Enterprises Ltd., Torrent Pharmaceuticals Ltd, NATCO Pharma Limited, Bilcare Limited, Cipla Limited, Sanofi India Limited, Glenmark Pharmaceuticals Limited and Strides ... Read more (Read more...)
Categories: Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biocon Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)